PIK3CA and follicular lymphoma: Several PI3K inhibitors, including copanlisib (Bayer), were approved by the FDA, though copanlisib was recently removed from the U.S. market due to insufficient efficacy in follicular lymphoma, despite its low toxicity in patients[54].